Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.

Rojas-Sepúlveda D, Tittarelli A, Gleisner MA, Ávalos I, Pereda C, Gallegos I, González FE, López MN, Butte JM, Roa JC, Fluxá P, Salazar-Onfray F.

Cancer Immunol Immunother. 2018 Mar 29. doi: 10.1007/s00262-018-2157-5. [Epub ahead of print] Review.

PMID:
29600445
2.

Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity.

Tittarelli A, Guerrero I, Tempio F, Gleisner MA, Avalos I, Sabanegh S, Ortíz C, Michea L, López MN, Mendoza-Naranjo A, Salazar-Onfray F.

Br J Cancer. 2016 Oct 25;115(9):e14. doi: 10.1038/bjc.2016.296. Epub 2016 Sep 22. No abstract available.

3.

Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity.

Tittarelli A, Guerrero I, Tempio F, Gleisner MA, Avalos I, Sabanegh S, Ortíz C, Michea L, López MN, Mendoza-Naranjo A, Salazar-Onfray F.

Br J Cancer. 2015 Jul 14;113(2):259-67. doi: 10.1038/bjc.2015.162. Epub 2015 Jul 2. Erratum in: Br J Cancer. 2016 Oct 25;115(9):e14.

4.

Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome.

Kawai VK, Avalos I, Oeser A, Oates JA, Milne GL, Solus JF, Chung CP, Stein CM.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):285-92. doi: 10.1002/acr.22169.

5.

Oxidative stress in fibromyalgia and its relationship to symptoms.

Chung CP, Titova D, Oeser A, Randels M, Avalos I, Milne GL, Morrow JD, Stein CM.

Clin Rheumatol. 2009 Apr;28(4):435-8. doi: 10.1007/s10067-008-1072-0. Epub 2008 Dec 17.

6.

Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus.

Avalos I, Rho YH, Chung CP, Stein CM.

Clin Exp Rheumatol. 2008 Sep-Oct;26(5 Suppl 51):S5-13. Review. No abstract available.

PMID:
19026140
7.

The role of complement in the antiphospholipid syndrome-associated pathology.

Avalos I, Tsokos GC.

Clin Rev Allergy Immunol. 2009 Jun;36(2-3):141-4. doi: 10.1007/s12016-008-8109-7. Review.

PMID:
19067251
8.

Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis.

Solus J, Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM.

Arthritis Rheum. 2008 Sep;58(9):2662-9. doi: 10.1002/art.23796.

9.

Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms.

Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, Sokka T, Raggi P, Pincus T, Stein CM.

Arthritis Rheum. 2008 Jul;58(7):2105-12. doi: 10.1002/art.23600.

10.

T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis.

Cohen RA, Bayliss G, Crispin JC, Kane-Wanger GF, Van Beek CA, Kyttaris VC, Avalos I, Yu CY, Tsokos GC, Stillman IE.

Clin Immunol. 2008 Jul;128(1):1-7. doi: 10.1016/j.clim.2008.04.004.

11.

N-terminal pro-brain natriuretic peptide in systemic lupus erythematosus: relationship with inflammation, augmentation index, and coronary calcification.

Chung CP, Solus JF, Oeser A, Avalos I, Kurnik D, Raggi P, Stein CM.

J Rheumatol. 2008 Jul;35(7):1314-9. Epub 2008 Jun 1.

12.

Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus.

Chung CP, Oeser A, Raggi P, Solus JF, Avalos I, Linton MF, Fazio S, Stein CM.

Clin Rheumatol. 2008 Oct;27(10):1227-33. doi: 10.1007/s10067-008-0890-4. Epub 2008 Apr 18.

PMID:
18421545
13.

Increased augmentation index in rheumatoid arthritis and its relationship to coronary artery atherosclerosis.

Avalos I, Chung CP, Oeser A, Gebretsadik T, Shintani A, Kurnik D, Raggi P, Sokka T, Pincus T, Stein CM.

J Rheumatol. 2007 Dec;34(12):2388-94. Epub 2007 Nov 15.

PMID:
18050386
14.

Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus.

Avalos I, Chung CP, Oeser A, Milne GL, Borntrager H, Morrow JD, Raggi P, Solus J, Stein CM.

Lupus. 2007;16(12):981-6.

PMID:
18042592
15.

Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus.

Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM.

J Rheumatol. 2007 Sep;34(9):1849-54. Epub 2007 Jul 15.

PMID:
17659756
16.

Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.

Asanuma Y, Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM.

Atherosclerosis. 2007 Dec;195(2):e135-41. Epub 2007 Jun 14.

17.

Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms.

Avalos I, Chung CP, Oeser A, Milne GL, Morrow JD, Gebretsadik T, Shintani A, Yu C, Stein CM.

Lupus. 2007;16(3):195-200.

PMID:
17432105
18.

Atherosclerosis and inflammation: insights from rheumatoid arthritis.

Chung CP, Avalos I, Raggi P, Stein CM.

Clin Rheumatol. 2007 Aug;26(8):1228-33. Epub 2007 Feb 2. Review.

PMID:
17273810
19.

Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis.

Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM.

Atherosclerosis. 2008 Feb;196(2):756-63. Epub 2007 Jan 30.

PMID:
17266963
20.

Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis.

Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM.

Arthritis Res Ther. 2006;8(6):R186.

21.
22.

High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors.

Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, Stein CM.

Ann Rheum Dis. 2007 Feb;66(2):208-14. Epub 2006 Aug 10.

24.

Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus.

Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM.

Arthritis Rheum. 2005 Nov;52(11):3651-9.

25.

Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors.

Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, Pincus T, Avalos I, Stein CM.

Arthritis Rheum. 2005 Oct;52(10):3045-53.

26.

Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication.

Más Lago P, Cáceres VM, Galindo MA, Gary HE Jr, Valcarcel M, Barrios J, Sarmiento L, Avalos I, Bravo JA, Palomera R, Bello M, Sutter RW, Pallansch MA, de Quadros CA.

Int J Epidemiol. 2001 Oct;30(5):1029-34.

PMID:
11689516
27.

Mechanism of enterovirus involvement in epidemic neuropathy: hypothesis regarding pathophysiology.

Lago PM, Guzmán MG, Sarmiento L, Pérez AB, Alvarez M, Capó V, Avalos I, Flores GK.

Med Hypotheses. 2001 Mar;56(3):339-47.

PMID:
11359357
28.

[Enterovirus meningoencephalitis in the last 5 years].

Bello M, Más Lago P, Palomera R, Castillo A, Amín N, Acosta B, Cartaya J, Avalos I.

Rev Cubana Med Trop. 1996;48(2):118-22. Spanish.

PMID:
9768282
29.

[Cuban epidemic neuropathy. III. Neutralizing antibodies to the strains isolated and to other enteroviruses in patients and healthy subjects].

Más Lago P, Balmaseda A, Avalos I, Castillo A, Guzmán MG, Llop A, Palomera R.

Rev Cubana Med Trop. 1995;47(1):21-5. Spanish.

PMID:
9805062

Supplemental Content

Loading ...
Support Center